Panagora Asset Management’s Xenon Pharmaceuticals XENE Stock Holding History

Panagora Asset Management’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$40.1M	Buy	+664,031	New	+$36.9M	0.12%	159

Other funds holding XENE

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

NFT

Nan Fung Trinity Central, Hong Kong, Hong Kong $1.01B AUM 64.38% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

PCM

Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

KBC Group Brussels, Belgium $46.3B AUM 43.9% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return

Panagora Asset Management's XENE Position: Q2 2026 in Review

Panagora Asset Management opened a new position in Xenon Pharmaceuticals (XENE) in Q2 2026: 664,031 shares worth $40.1M. The stake represents 0.12% of the portfolio and ranks #159 among its holdings.

80 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

Panagora Asset Management held 664,031 shares of Xenon Pharmaceuticals worth $40.1M as of Q2 2026.
Xenon Pharmaceuticals was a new Panagora Asset Management position in Q2 2026.
Xenon Pharmaceuticals made up 0.12% of Panagora Asset Management's portfolio in Q2 2026, its #159 holding.
80 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Panagora Asset Management's 13F filing for Q2 2026, filed 6 Aug 2026.